keyword
MENU ▼
Read by QxMD icon Read
search

olivera pável

keyword
https://www.readbyqxmd.com/read/26709028/eltrombopag-safety-and-efficacy-for-primary-chronic-immune-thrombocytopenia-in-clinical-practice
#1
Tomás José González-López, María Teresa Alvarez-Román, Cristina Pascual, Blanca Sánchez-González, Fernando Fernández-Fuentes, Isidro Jarque, Gloria Pérez-Rus, Susana Pérez-Crespo, Silvia Bernat, José Angel Hernández-Rivas, Marcio M Andrade, Montserrat Cortés, Marta Gómez-Nuñez, Pavel Olivera, Violeta Martínez-Robles, Angeles Fernández-Rodríguez, Miguel Angel Fuertes-Palacio, Carmen Fernández-Miñano, Erik de Cabo, Rosa Fisac, Carlos Aguilar, Abelardo Bárez, María Jesús Peñarrubia, Luis Javier García-Frade, José Ramón González-Porras
BACKGROUND: Eltrombopag is effective and safe in chronic immune thrombocytopenia (ITP). However, clinical trials may not accurately reflect what happens in clinical practice. We evaluated the efficacy and safety of eltrombopag in primary chronic ITP in a real-world setting. METHODS: A total of 164 primary patients with chronic ITP from 40 Spanish centers, who had been treated with eltrombopag, were retrospectively evaluated. RESULTS: The median age of our cohort (72% women) was 63 yr (interquartile range, IQR, 45-75 yr)...
September 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/26036227/beyond-hemostasis-the-challenge-of-treating-plasminogen-deficiency-a-report-of-three-cases
#2
Verónica Pons, Pável Olivera, Roberto García-Consuegra, Laura López-Andreoni, Nieves Martín-Begué, Angel García, Juliana Hidalgo, Francesc Bosch, Amparo Santamaría
Congenital plasminogen deficiency is a rare autosomal recessive disorder, characterized by chronic mucosal membranous lesions. Although the most common clinical manifestation is eye involvement as ligneous conjunctivitis, extra-ocular lesions affecting other mucosal surfaces indicates a systemic disease. In this report we describe two cases with atypical extra-ocular involvement that includes pericarditis and recurrent hematocolpos, and one with paradoxical correlation between ocular lesions and plasminogen levels...
April 2016: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/25521630/use-of-eltrombopag-after-romiplostim-in-primary-immune-thrombocytopenia
#3
MULTICENTER STUDY
José Ramón González-Porras, María Eva Mingot-Castellano, Marcio M Andrade, Rafael Alonso, Isabel Caparrós, María Carmen Arratibel, Fernando Fernández-Fuertes, Maria José Cortti, Cristina Pascual, Blanca Sánchez-González, Silvia Bernat, Miguel Angel Fuertes-Palacio, Juan Andrés Vázquez-Paganini, Pavel E Olivera, María Teresa Alvarez-Román, Isidro Jarque, Montserrat Cortés, Violeta Martínez-Robles, Francisco Javier Díaz-Gálvez, María Calbacho, Carmen Fernández-Miñano, Javier Garcia-Frade, Tomás José González-López
The thrombopoietin receptor agonists (THPO-RAs), romiplostim and eltrombopag, are effective and safe in immune thrombocytopenia (ITP). However, the value of their sequential use when no response is achieved or when adverse events occur with one THPO-RA has not been clearly established. Here we retrospectively evaluated 51 primary ITP adult patients treated with romiplostim followed by eltrombopag. The median age of our cohort was 49 (range, 18-83) years. There were 32 women and 19 men. The median duration of romiplostim use before switching to eltrombopag was 12 (interquartile range 5-21) months...
April 2015: British Journal of Haematology
https://www.readbyqxmd.com/read/25400215/successful-discontinuation-of-eltrombopag-after-complete-remission-in-patients-with-primary-immune-thrombocytopenia
#4
MULTICENTER STUDY
Tomás José González-López, Cristina Pascual, María Teresa Álvarez-Román, Fernando Fernández-Fuertes, Blanca Sánchez-González, Isabel Caparrós, Isidro Jarque, María Eva Mingot-Castellano, José Angel Hernández-Rivas, Mónica Martín-Salces, Laura Solán, Paola Beneit, Reyes Jiménez, Silvia Bernat, Marcio M Andrade, Montserrat Cortés, Maria José Cortti, Susana Pérez-Crespo, Marta Gómez-Núñez, Pavel E Olivera, Gloria Pérez-Rus, Violeta Martínez-Robles, Rafael Alonso, Angeles Fernández-Rodríguez, María Carmen Arratibel, María Perera, Carmen Fernández-Miñano, Miguel Angel Fuertes-Palacio, Juan Andrés Vázquez-Paganini, Isabel Gutierrez-Jomarrón, Inés Valcarce, Erik de Cabo, Adriana Sainz, Rosa Fisac, Carlos Aguilar, María Paz Martínez-Badas, María Jesús Peñarrubia, María Calbacho, Carmen de Cos, Manuel González-Silva, Erika Coria, Arancha Alonso, Alberto Casaus, Armando Luaña, Pilar Galán, Cristina Fernández-Canal, Javier Garcia-Frade, José Ramón González-Porras
Eltrombopag is effective and safe in immune thrombocytopenia (ITP). Some patients may sustain their platelet response when treatment is withdrawn but the frequency of this phenomenon is unknown. We retrospectively evaluated 260 adult primary ITP patients (165 women and 95 men; median age, 62 years) treated with eltrombopag after a median time from diagnosis of 24 months. Among the 201 patients who achieved a complete remission (platelet count >100 × 10(9) /l), eltrombopag was discontinued in 80 patients...
March 2015: American Journal of Hematology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"